Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > International Molecular Screening Program for… >

International Molecular Screening Program for Metastatic Breast Cancer AURORA at IMPAKT

Published: May 7, 2014.
Released by Breast International Group (BIG)-aisbl  

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant improvements in survival have been made, metastatic breast cancer represents the leading cause of death among patients with the disease.

In this context the Breast International Group (BIG) recently launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several 1000 more patients.

Dr Martine Piccart-Gebhart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, strongly believes in this research programme and says: "It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future".

Within AURORA, metastatic and primary breast cancer tissue specimens will be collected and screened with a panel of more than 400 cancer-related genes for the first time on a large scale. Plasma and blood samples will also be collected, and any samples not analysed immediately will be stored in an independent bio-repository to enable future research. An innovative bioinformatics platform has been developed to support the collection of AURORA data. These data are being collected in a way that will allow sharing and collaborating in the context of other initiatives started by researchers in North America.

AURORA will enable scientists to understand both why breast cancer metastasises and why some patients respond poorly to standard treatment, while others respond very well. Whenever possible, patients participating in AURORA will be offered to participate in a clinical trial testing new and promising drugs that target the specific genetic characteristics of their tumours. The ultimate hope is that AURORA will benefit patients by leading us to both better treatments and to finding cures for the women and men affected by this disease.




The above story is based on materials provided by Breast International Group (BIG)-aisbl.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Cancer 
4/3/11 
★★★ 
DNA of 50 Breast Cancer Patients Decoded
In the single largest cancer genomics investigation reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched …
Women 
6/11/12 
★★★ 

Decoding DNA Finds Breast Tumor Signatures That Predict Treatment Response
Metastatic 
1/27/14 
Drug to Reverse Breast Cancer Spread in Development
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells. The vast majority of deaths from cancer result from …
Treatment 
3/24/10 
What Should Be the Goal of Treatment in Metastatic Breast Cancer?
Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over …
Cent 
10/1/12 
★★ 
Biological Markers Increase Clinical Trial Success Rate of New Breast Cancer Drugs
Using biological markers--genetic characteristics that are associated with some patients with breast cancer--can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, …
Cancer 
7/20/11 
TGen, Virginia G. Piper Cancer Center Studying New Breast Cancer Drug
SCOTTSDALE, Ariz. — July 20, 2011 — A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational …
Patients 
7/1/11 
Worse Outcomes for Older Breast Cancer Patients with Other Health Problems
Older breast cancer patients with certain other health problems have higher mortality rates than patients without these problems according to a study published online June 30 in the Journal …
Cancer 
5/19/11 
Blood Test Confirmed to Be 'Powerful Predictor' Following Largest Analysis to Date
Washington, DC – Researchers at Georgetown Lombardi Comprehensive Cancer Center say the number of circulating tumor cells (CTCs) in the blood is a "powerful predictor" to help physicians more …
Mackey 
12/13/13 
New Combination Therapy Fails to Delay Progression of Advanced Breast Cancer
SAN ANTONIO — Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of …
Percent 
12/7/11 
Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events
A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence …
Entinostat 
11/14/11 
Benefit of Novel Drug in Breast Cancer Seen in Blood Within Weeks
Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the …
Event 
12/10/10 
Denosumab Delayed Time to First Skeletal-related Side Effect
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile